594865-02-8

Basic information

• Product Name: 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 6-(methylthio)-N-(phenylmethyl)-
• CAS NO: 594865-02-8
• Molecular Formula: C13H13N5S
• Molecular Weight: 271.346
• Mol File: 594865-02-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 6-(methylthio)-N-(phenylmethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 6-(methylthio)-N-(phenylmethyl)-(594865-02-8)
• EPA Substance Registry System: 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 6-(methylthio)-N-(phenylmethyl)-(594865-02-8)

Safety Data

• Hazardous Substances Data: 594865-02-8(Hazardous Substances Data)

Usage

Chemical class

pyrazolopyrimidine

Structure

contains a pyrimidine ring fused to a pyrazole ring and an amine group

Substituents

methylthio group at the sixth position, phenylmethyl group attached to the amine nitrogen atom

Potential applications

pharmaceutical or biological relevance

Possible future studies

medicinal chemistry or other fields

Upstream product

• 24521-76-4 4-hydroxy-6-mercapto-1H-pyrazolo[3,4-d]pyrimidine 
• 5334-26-9 4-hydroxy-6-methylmercapto-1H-pyrazolo[3,4-d]pyrimidine 
• 85426-79-5 4-chloro-6-methylmercapto-1H-pyrazolo[3,4-d]pyrimidine 
• 100-46-9 benzylamine 

Downstream Products

• 594865-04-0 benzyl-(1-methyl-6-methylsulfanyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine 
• 594865-10-8 benzyl-(1-isopropyl-6-methanesulfonyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine 
• 594865-09-5 benzyl-(6-methanesulfonyl-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine 
• 594865-08-4 benzyl-(6-methanesulfonyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine 
• 594865-05-1 benzyl-(1-isopropyl-6-methylsulfanyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine 

Relevant articles and documents

Synthesis and biological evaluations of pyrazolo[3,4-d]pyrimidines as cyclin-dependent kinase 2 inhibitors

A series of 1,4,6-trisubstituted pyrazolo[3,4-d]pyrimidines 15-19, 30-38 capable of selectively inhibiting CDK2 activity were synthesized by derivatization at C-4, C-6 and N-1 with various amines and lower alkyl groups. For above synthetic compounds, biological evaluation was carried out and structure-activity relationship was examined. In our series, 4-anilino compounds exhibited better CDK2 inhibitory activity and antitumor activity compared to 4-benzyl compounds. The compounds 33a,b having a 3-fluoroaniline group at C-4 showed comparable or superior CDK2 inhibitory activity to those of olomoucine and roscovitine as reference compounds. In general, the unsubstituted compounds (30a,b, 33a,b, 36a,b) at N-1 possessed higher potency than the substituted compounds (32a,b, 34a,b) for the CDK2 inhibitory activity. As for EGFR inhibitory activity, most compounds didnot have a significant activity. The compounds 32a,b exhibited potent cell growth inhibitory activity against human cancer cell lines, but their CDK2 inhibitory activities were slightly poorer than olomoucine.